BRCA Counseling Guideline Improves Decision Making

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

SAN FRANCISCO--Establishing clinical care guidelines for hereditary (BRCA1 or BRCA2) breast cancer is increasingly important for managed care organizations as well as private physicians, Susan Kutner, MD, said at the American Cancer Society Second National Conference on Cancer Genetics.

SAN FRANCISCO--Establishing clinical care guidelines for hereditary (BRCA1 or BRCA2) breast cancer is increasingly important for managed care organizations as well as private physicians, Susan Kutner, MD, said at the American Cancer Society Second National Conference on Cancer Genetics.

She said that instituting such guidelines at her HMO--Kaiser Permanente in Northern California--increased staff awareness about the issues facing genetic cancer patients and led to higher quality care. Dr. Kutner is chair of the Northern California Kaiser Breast Cancer Task Force and chief of surgery in San Jose.

The medical professionals who spearheaded the Kaiser project nationally set out to determine how to use BRCA counseling most effectively to reduce breast cancer morbidity and mortality. In so doing, they hoped to gain experience in the collaborative development of outcomes-based guidelines for genetic technologies and thus lay the foundation for other genetic guidelines, "not just those affecting breast cancer," she said.

After development, the BRCA guideline was reviewed by a wide cross-section of the community, including breast cancer advocates, consumer groups, professional organizations, and legislators. The guideline established criteria for both genetic testing and counseling and requires that the testing be ordered by a medical geneticist.

Women May Overestimate or Underestimate Their Risk

"Many patients have an inflated or a deflated idea of their risk. Guidelines are important because they assist the patient and her primary care provider in the decision about whether to test," Dr. Kutner commented.

The guideline was designed specifically to focus on counseling of women and families at high risk and to develop the multidisciplinary support for needed follow-up.

The guideline recommends BRCA counseling for women whose family histories shows early onset, bilateral breast cancer and multiple first-degree relatives with breast cancer. Prenatal testing is not recommended, nor is testing advised for females under age 18.

Educational Materials

"Before testing, educational materials about the test are provided to patients," Dr. Kutner said. Counselors do an in-depth risk assessment and advise patients about other issues such as insurability, confidentiality, and discrimination, as well as provide assistance in developing psychosocial support. Informed consent is then obtained, and follow-up visits are scheduled.

As part of its new guideline, Kaiser is currently establishing a BRCA data registry, to keep tabs on the outcomes of patients who have had genetic counseling and testing.

To promote the guideline, Kaiser offers in-depth educational opportunities, including video conference lectures for physicians, health information tapes for patients, and in-depth seminars for clinical care experts.

Dr. Kutner noted that the cost of instituting the genetic counseling guideline is not yet known, and the stakes of caring for such patients are high.

"We want to make wise investments with our money and technology to best benefit our patients," she said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content